At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 96 enrolled
Drug / intervention
Abivertinib +1 moredrug
Likely dose
Abivertinib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19
In Brief
A Phase 2 clinical trial evaluating Abivertinib and Standard of Care for Covid-19. Completed, enrolled 96 participants across 6 sites.
Detailed Summary
Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid-19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartOct 2020
Primary CompletionJul 2021
Study CompletionAug 2021
TodayJul 2026
First PostedJun 19, 2020
Enrollment StartOct 9, 2020
Primary CompletionJul 1, 2021
Study CompletionAug 23, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.0 years ago
Interventions
Abivertinibdrug
Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.
Standard of Careother
Standard of Care as determined by the Investigator